
Innoviva, Inc. (NASDAQ:INVA – Free Report) – Equities research analysts at HC Wainwright lowered their Q4 2026 earnings per share (EPS) estimates for Innoviva in a report released on Friday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of $0.53 for the quarter, down from their previous forecast of $0.54. The consensus estimate for Innoviva’s current full-year earnings is $1.52 per share. HC Wainwright also issued estimates for Innoviva’s Q3 2027 earnings at $0.57 EPS and Q4 2027 earnings at $0.63 EPS.
Innoviva (NASDAQ:INVA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($1.55). The firm had revenue of $106.12 million during the quarter, compared to analyst estimates of $115.31 million. Innoviva had a return on equity of 22.91% and a net margin of 44.13%.
Get Our Latest Research Report on INVA
Innoviva Stock Performance
Innoviva stock opened at $19.03 on Monday. The company has a current ratio of 15.44, a quick ratio of 14.58 and a debt-to-equity ratio of 0.23. Innoviva has a 1 year low of $18.66 and a 1 year high of $25.15. The company has a market cap of $1.35 billion, a PE ratio of 9.56, a PEG ratio of 4.16 and a beta of 0.38. The company’s 50-day moving average is $20.70 and its two-hundred day moving average is $21.85.
Institutional Investors Weigh In On Innoviva
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Innoviva during the 2nd quarter worth about $77,562,000. Dimensional Fund Advisors LP increased its stake in shares of Innoviva by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock valued at $103,366,000 after acquiring an additional 76,026 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Innoviva in the 2nd quarter valued at about $37,873,000. Deutsche Bank AG acquired a new stake in shares of Innoviva in the 2nd quarter valued at approximately $20,847,000. Finally, William Blair Investment Management LLC raised its position in shares of Innoviva by 29.7% in the 3rd quarter. William Blair Investment Management LLC now owns 832,881 shares of the biotechnology company’s stock valued at $17,665,000 after acquiring an additional 190,705 shares during the period. 99.12% of the stock is owned by institutional investors and hedge funds.
About Innoviva
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
Further Reading
- Five stocks we like better than Innoviva
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
